NGQ1 Stock Overview
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medicure Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.73 |
| 52 Week High | CA$1.16 |
| 52 Week Low | CA$0.66 |
| Beta | 1 |
| 1 Month Change | -3.95% |
| 3 Month Change | -3.31% |
| 1 Year Change | -16.09% |
| 3 Year Change | -23.16% |
| 5 Year Change | -81.35% |
| Change since IPO | -96.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| NGQ1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | -16.1% | -19.9% | 0.9% |
Return vs Industry: NGQ1 exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: NGQ1 underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| NGQ1 volatility | |
|---|---|
| NGQ1 Average Weekly Movement | 22.6% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NGQ1's share price has been volatile over the past 3 months.
Volatility Over Time: NGQ1's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Albert Friesen | www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
| NGQ1 fundamental statistics | |
|---|---|
| Market cap | €7.69m |
| Earnings (TTM) | -€629.15k |
| Revenue (TTM) | €14.80m |
0.5x
P/S Ratio-11.7x
P/E RatioIs NGQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGQ1 income statement (TTM) | |
|---|---|
| Revenue | CA$21.69m |
| Cost of Revenue | CA$7.71m |
| Gross Profit | CA$13.99m |
| Other Expenses | CA$14.91m |
| Earnings | -CA$922.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.088 |
| Gross Margin | 64.48% |
| Net Profit Margin | -4.25% |
| Debt/Equity Ratio | 0% |
How did NGQ1 perform over the long term?
See historical performance and comparison